Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

Interventions

DRUG: Vamifeport
DRUG: Placebo

Sponsor

CSL Behring